3 citations
,
July 2018 in “Cureus” This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.
12 citations
,
March 2021 in “Patient Preference and Adherence” This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.
January 1987 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” This review discusses hormonal therapies for acne related to endocrine disorders and provides practical guidelines for managing hormonally influenced acne in clinical practice, but reports no new clinical results.
December 2021 in “Research Square (Research Square)” This study suggests that certain nutraceuticals may enhance the inhibitory effects of tamoxifen on estrogen in breast cancer cells and potentially offer protective benefits for hair growth in patients undergoing endocrine therapy.
February 2022 in “Research Square (Research Square)” In this cell-based study, researchers found that certain nutraceuticals combined with tamoxifen may influence estrogen receptor expression, potentially offering a protective effect and promoting hair growth during breast cancer therapy.
